<b>Index to Posts on Biolex</b> [Updated entries on Locteron.] Biolex has a production platform for protein drugs that uses transgenic plants. Here's a partial list of relevant posts: <b><u>CD20 and other mAb programs</u></b> <a href='read_msg.asp?message_id=25179852'>#msg-25179852</a> CD20/Rituxan FoB program <a href='read_msg.asp?message_id=26942457'>#msg-26942457</a> Collaboration with Merck Serono <a href='read_msg.asp?message_id=19450622'>#msg-19450622</a> Collaboration with Genmab <a href='read_msg.asp?message_id=15116312'>#msg-15116312</a> Homogeneity of glycosylation <a href='read_msg.asp?message_id=5919466'>#msg-5919466</a> ‘Plantibody’ patent <b><u>Locteron program in HCV</u></b> <a href='read_msg.asp?message_id=32662307'>#msg-32662307</a> Biolex acquires full rights to Locteron <a href='read_msg.asp?message_id=28786162'>#msg-28786162</a> Phase-2a Locteron data <b><u>Corporate and miscellaneous</u></b> <a href='read_msg.asp?message_id=21229000'>#msg-21229000</a> BLX-155 clot-buster program <a href='read_msg.asp?message_id=32662762'>#msg-32662762</a> Biolex raises $60M for VC’s <a href='read_msg.asp?message_id=26487825'>#msg-26487825</a> IPO withdrawal (2/08)